Metagenomic Sequencing Market – Trends Forecast Till 2030

Market Snapshot

Market Overview

The global Metagenomic Sequencing Market size is projected to reach a CAGR of 19.1% from 2023-2030.

"Metagenomics" is the two words "meta" and "genomics". So, genomics is obtaining the DNA sequence, but meta implies that we're doing it of many organisms together. And metagenomics is usually used when we are studying microbial communities where we can't separate one microbe from another. Like there may be two bacteria that grow together, and so when you take the DNA sequence, you're getting the DNA sequence of two bacteria together.

Growth in the Metagenomic Sequencing Market can largely be attributed to factors such as Growth in the metagenomic sequencing market is mainly driven by continuous technological innovations in NGS platforms, increasing initiatives and funding from government & private bodies for large-scale sequencing projects, declining costs of genome sequencing, and the significant applications of metagenomics in various fields. Continuous technological innovations in sequencers have enabled the introduction of efficient, portable, and easy-to-use NGS platforms, capable of providing rapid and accurate results and boasting improved turnaround times. The introduction of such products and technologies provides an immediate competitive edge to players; as a result, prominent companies are increasingly focusing on R&D to strengthen their market positions and shares.

On the other hand, lack of skilled professionals and requirement of advance, more efficient and robust bioinformatics tools hamper the growth of the market.

The overall impact of COVID-19 pandemic is likely to remain positive for the metagenomics sequencing market. As, throughout the COVID-19 pandemic, clinical diagnostics and testing is a critical component of the response and is on a rapid increase with the rise in number of cases, which enables rapid identification and isolation of infected individuals. The majority of this testing is PCR-based, detecting the presence of the SARS-CoV-2 virus; thereby, having a positive impact on the market.

Delvens Industry Expert's Standpoint

The need for microbiome analysis and an increased understanding of the importance of the microbiome to human health are driving the market for metagenomic sequencing, which is expanding quickly. Metagenomic sequencing is now more widely used in a variety of applications, including drug discovery, environmental monitoring, and disease diagnosis. This is because the development of high-throughput sequencing technologies has made it simpler and more affordable to sequence large amounts of genetic material from complex samples. The market for metagenomic sequencing is predicted to continue expanding at a rapid clip, with North America being the largest regional market, followed by Europe and Asia-Pacific. Overall, the market for metagenomic sequencing offers enormous prospects for businesses engaged in the sector. Companies may obtain a competitive edge and take a piece of the expanding market by investing in R&D activities, releasing new goods, and developing strategic alliances and collaborations.

Market Portfolio

Key Findings

• The product & service segment is further segmented into reagents & consumables, instruments, services, and analysis & data interpretation solutions. The reagents & consumables segment is expected to share and reach the highest CAGR during the forecast period. Factors such as the development and commercialization of high-quality reagents and kits and the continuous requirement of sequencing reagents by end users are expected to drive the growth of this segment in the market.
   
• The technology segment is further segmented into Shotgun Metagenomic Sequencing, 16S rRNA Sequencing, and Metatranscriptomics. 16S rRNA sequencing segment accounted for the largest share of the metagenomic sequencing market. The high accuracy and affordability offered by 16S rRNA sequencing, advancements in bioinformatics solutions, and the growing number of metagenomic research activities to identify and classify various bacterial strains are the major factors driving the growth of the 16S rRNA sequencing market.
   
• The application segment is further segmented into drug discovery, clinical diagnostics, soil microbiome applications, industrial applications, ecological & environmental applications, veterinary applications, and other applications. The drug discovery segment is expected to reach the highest CAGR during the forecast period. The surge in the segment is due to increasing research activities for novel drug discovery and growing collaborations between market players, academic institutions, and pharmaceutical companies for drug development.

Regional Analysis

North America to Dominate the Market

• North America accounted for the largest share of the metagenomic sequencing market in 2021. Factors such as the increasing applications of metagenomics in diagnostics and genomics research, the availability of research funding, and the development of NGS data analysis solutions are driving the growth of the metagenomic sequencing market in North America.
   
• The market in the Asia Pacific is expected to register the highest growth rate during the forecast period, primarily due to the increasing financial support from public as well as private agencies, the increasing number of NGS-based research projects, increasing awareness about precision medicine, and the rising prevalence of chronic diseases.

Competitive Landscape

•   Illumina, Inc.
•   Thermo Fisher Scientific, Inc.
•   QIAGEN N.V.
•   PerkinElmer
•   Oxford Nanopore Technologies Ltd.
•   BGI Group
•   Macrogen Inc.
•   GENEWIZ
•   Eurofins Scientific
•   Novogene Corporation

Recent Developments

• In January 2021, Illumina, Inc. (US) collaborated with Helix to increase national surveillance infrastructure in the US to track the emergence and prevalence of novel strains of SARS-CoV-2 with support from the CDC.
   
• In June 2020, Illumina (US) acquired BlueBee, a cloud-based software company that provides genomic analysis solutions for research and clinical customers. Through this acquisition, Illumina enhanced its capabilities to analyze and interpret the data produced by its sequencing systems.

Reasons to Acquire

• Increase your understanding of the market for identifying the best and suitable strategies and decisions on the basis of sales or revenue fluctuations in terms of volume and value, distribution chain analysis, market trends and factors.
   
• Gain authentic and granular data access for Metagenomic Sequencing Market so as to understand the trends and the factors involved behind changing market situations.
   
• Qualitative and quantitative data utilization to discover arrays of future growth from the market trends of leaders to market visionaries and then recognize the significant areas to compete in the future.
   
• In-depth analysis of the changing trends of the market by visualizing the historic and forecast year growth patterns.

Report Scope